🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

ISTH is inviting all clinicians involved in anticoagulation management to participate in the following survey: redcap.slhd.nsw.gov.au/surveys/?s=7K4… These are the outcomes they are interested in. Jump on the link and fill it out! #ISTH2025 THANZ

In a Star Wars themed presentation, Julianne Chong, recipient of an THANZ travel grant, laid down the case for Anticoagulation Stewardship (ACS) in all hospital settings, and invited participation in an ISTH endorsed survey to examine variation in current ACS practice.

Dr Isabelle Gouin-Thibault gave an update on the ongoing Delphi process to develop ISTH guidelines for the challenging area of UFH monitoring and nomogram based dose adjustment. #ISTH2025

The #ISTH2025 Opening ceremony is under way! ISTH President is giving opening remarks on the importance of global collaboration and knowledge exchange:

A fitting tribute to the life’s work of Claire McLintock delivered in the Claire McLintock Memorial Lecture by Jennifer Curnow. Congratulations Jennifer, THANZ is proud of you! #ISTH2025

Dr Uma Athale gave an excellent SOA update on thromboprophylaxis in pediatric cancer ?who, when, with what and for how long…more questions than answers right now! Work to be done #ISTH2025 THANZ

Is this the end of rivaroxaban for acute VTE? Lana Castellucci presenting the COBBRA trial - 1st RCT comparing apixaban to riva over 3 months. 56% reduction in bleeding risk with apixaban. A safer Rx with the same efficacy. #ISTH2025

Late breaking abstract session at #ISTH2025. COBRRA results are in! 50% reduction in bleeding with Apixaban use for acute VTE compared to Rivaroxaban. THANZ members were co-investigators on this study, an enormous effort.

E. Vincent S. Faustino beautiful summary of 2-hit hypothesis for CVC related VTE in critically ill kids, role of inflammation, need to decouple hemostasis from thrombosis, potential role for XI / XIIa inhibitors, and maybe adolescents aren’t just young adults… #ISTH2025 THANZ

THANZ Congratulations Lana Castellucci and the entire study team ! Incredible work on this pivotal trial !

Promising phase1/2 data on NXT007 prophylaxis presented by Midori Shima at #ISTH2025. Can we achieve “normal range” FVIII equivalence? We look forward to phase 3 studies and further data around ADA risk.

Biology resists simplicity #ISTH2025 plenary session. THANZ

#ISTH2025!! Thanks Anticoagulation Forum /ISTH for allowing me to launch our Anticoagulation Stewardship Periop Survey/present my ICU intervention poster, THANZ for the travel grant to get me here + Lana Castellucci Darren Triller Geoff Barnes Jean Connors, Vivien Chen Jonathan Penm, PhD, FFIP FAdPha FPS FANZCAP FHEA ❤️

Critical appraisal of the ISTH Haemophilia Guidelines session, with some robust discussion and interesting perspectives, our very own Dr Jane Mason delivering a great presentation “Dissecting the Guidelines” the clinician experience #ISTH2025 THANZ

Mark Skinner highlighting the danger of over-reliance on RCTs during guideline development for rare conditions like haemophilia #ISTH2025 THANZ

What a great plenary lecture of Leslie Raffini at #ISTH2025 Pediatric Thrombosis: a lot has been done in 30 years, but still a lot to be done in the coming years!

👏 A truly encouraging session today at the #ISTHCongress on the ISTH haemophilia guidelines. The open and constructive dialogue reflects the progress we’ve made collectively as a global community. This evolving landscape highlights the value of ongoing collaboration and mutual

Sustained and stable FIX levels have now been repeatedly been observed across multiple #genetherapy clinical trials for #hemophila B. Will extend the red line tomorrow at Clinical Gene Therapy session at #ISTH2025.

THANZ are thrilled that Jean will be one of our keynote speakers at our national Blood conference in Perth in October! Looking forward to it! #ISTH2025 #Blood2025

Observational data (n=506) demonstrating superior safety and efficacy of low dose apixaban compared to VKA in cirrhotic PVT. Even Child C cirrhosis was represented. #ISTH2025 THANZ